Consensus Day One Biopharmaceuticals, Inc.

Equities

DAWN

US23954D1090

Real-time Estimate Cboe BZX Other stock markets 12:06:40 04/05/2024 am IST			5-day change	1st Jan Change
17.38 ^USD	-1.05%		+16.49%	+19.04%

29/04	North American Morning Briefing : Investors Brace -2-	DJ
24/04	Needham Adjusts Price Target on Day One Biopharmaceuticals to $33 From $30, Keeps Buy Rating	MT

Evolution of the average Target Price on Day One Biopharmaceuticals, Inc.

Price target over the last 5 years

History of analyst recommendation changes

bd0c19.pfyBTQkDWJmicDhMLum5lgPiOMRuY2LZ4gLuoEIC2XI.17rCeWYuLeDvRWg0Vo-B01WpVekcLRu0s1rX0Apx6D_qv8oDZUkaz5McTw~462e4a1834e07a44802f205351a6cade

Analyst Recommendations on Day One Biopharmaceuticals, Inc.

Needham Adjusts Price Target on Day One Biopharmaceuticals to $33 From $30, Keeps Buy Rating	24/04	MT
JPMorgan Raises Price Target on Day One Biopharmaceuticals to $36 From $32, Maintains Overweight Rating	22/04	MT
Piper Sandler Cuts Price Target on Day One Biopharmaceuticals to $40 From $45, Maintains Overweight Rating	28/02	MT
Wedbush Adjusts Day One Biopharmaceuticals' Price Target to $33 From $35, Keeps Outperform Rating	27/02	MT
Goldman Sachs Cuts Price Target on Day One Biopharmaceuticals to $44 From $50, Maintains Buy Rating	27/02	MT
Wedbush Lowers Day One Biopharmaceuticals' Price Target to $35 From $39, Keeps Outperform Rating	07/11	MT
Wedbush Lifts Day One Biopharmaceuticals' PT to $39 From $38 After Tovorafenib Receives Priority Review, Maintains Outperform Rating	31/23/31	MT
Goldman Sachs Lowers Price Target on Day One Biopharmaceuticals to $54 From $63, Maintains Buy Rating	08/23/08	MT
HC Wainwright Raises Price Target on Day One Biopharmaceuticals to $50 From $45, Keeps Buy Rating	05/23/05	MT
Needham Cuts Price Target on Day One Biopharmaceuticals to $40 From $44, Maintains Buy Rating	08/23/08	MT
BofA Securities Downgrades Day One Biopharmaceuticals to Underperform From Buy, Adjusts Price Target to $9 From $34	25/23/25	MT
Needham Adjusts Price Target on Day One Biopharmaceuticals to $44 From $48, Keeps Buy Rating	05/23/05	MT
Capital One Starts Day One Biopharmaceuticals at Overweight With $40 Price Target	08/23/08	MT
Oppenheimer Initiates Coverage on Day One Biopharmaceuticals With Perform Rating	03/23/03	MT
Piper Sandler Adjusts Day One Biopharmaceuticals' Price Target to $45 From $40, Keeps Overweight Rating	09/23/09	MT
HC Wainwright Adjusts Price Target on Day One Biopharmaceuticals to $45 From $35, Maintains Buy Rating	09/23/09	MT
Goldman Sachs Adjusts Price Target on Day One Biopharmaceuticals to $62 From $45, Maintains Buy Rating	09/23/09	MT
Wedbush Raises Day One Biopharmaceuticals' PT to $38 From $35 After Positive Topline Results From FIREFLY-1 Study, Keeps Outperform Rating	09/23/09	MT
HC Wainwright Initiates Coverage on Day One Biopharmaceuticals With Buy Rating, $35 Price Target	15/22/15	MT
Needham Initiates Coverage on Day One Biopharmaceuticals With Buy Rating, $40 Price Target	14/22/14	MT
Goldman Sachs Initiates Day One Biopharmaceuticals With Buy Rating, Sets Price at $45	05/22/05	MT
BofA Securities Starts Day One Biopharmaceuticals at Buy With $34 Price Target	01/22/01	MT
Piper Sandler Adjusts Price Target on Day One Biopharmaceuticals to $40 From $35, Reiterates Overweight Rating	21/22/21	MT
Wedbush Lifts Price Target on Day One Biopharmaceuticals to $35 From $32, Citing Tovorafenib Data; Outperform Rating Kept	13/22/13	MT
Wedbush Removes Outperform-Rated Day One Biopharmaceuticals From Best Ideas List; Price Target is $32	13/22/13	MT